Newsroom 2016
Everything BrainStorm published in 2016.
Latest from BrainStorm
Brainstorm Reports on Successful End of Phase 2 Meeting with FDA, Upcoming Phase 3 Trial and Planned Application for Hospital Exemption for NurOwn®
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided a corporate update and announced its clinical development objectives for 2017.
21st Century Cures Act Passed by U.S. Congress Provides an Accelerated Approval Pathway for Regenerative Medicine Therapies
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced its support for the 21st Century Cures Act. The Act, which has been passed by both houses of congress and is expected to be signed into law in the near future
In-Depth Analyses Presented at International Symposium on ALS/MND Suggest Strong Biological Effect for NurOwn; Evidence of Halting of Disease Progression
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that new data from the Company's Phase 2 study of NurOwn in ALS were presented by lead investigator Dr. James Berry at the 27th International Symposium on ALS/MND
BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call on December 19 at 8:30 am Eastern Time. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer, wi
BrainStorm Announces NurOwn Data to be Highlighted at the 27th International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today data from the Company's Phase 2 study of NurOwn in ALS, will be highlighted in presentations at the 27th International Symposium on ALS/MND, being held Decem
BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2016.
BrainStorm Granted United States Patent for its Stem Cell Technology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has been granted United States Patent No. 9,474,787 titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
BrainStorm CEO to Present at Two Investor Conferences in September
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at two upcoming investor conferences: The Rodman & Renshaw 18th Annual
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2016.
BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn in Patients with ALS. The study achieve
BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn in Patients with ALS on Monday, July 18, 2016. The Company will host a conference call and
BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting Thursday, May 19 th, at the 11th World Stem Cells & Regenerative Medicine Congress in
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1,470,000 from Israel's Office of
BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2016.
Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf, VP Scientific & Regulatory Affairs will be presenting at the ISRASTEM 2016 and the 6th Israel Stem Cell Society (ISCS) joint an
BrainStorm Announces Financial Results for 2015 and Provides Business Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015. Brainstorm filed its annual report on Form 10-K reporting the results on Marc
BrainStorm to Present at Bio-Asia-International and ARM Investor Day Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting at two upcoming conferences.
BrainStorm's NurOwn for the Treatment of ALS Published in JAMA Neurology
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA Neurology discussing the outcome of the first in man Phase 1/2 study and Phase 2 dose escalat
BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn Trial in ALS at Hadassah Medical Center
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical Center in Jerusalem, Israel, to conduct the planned multi dose Phase 2 trial
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.